Sana Biotechnology (NASDAQ:SANA) Sets New 12-Month Low – Here’s What Happened

Sana Biotechnology, Inc. (NASDAQ:SANA)’s stock price reached a new 52-week low during trading on Monday . The company traded as low as $2.35 and last traded at $2.42, with a volume of 227929 shares traded. The stock had previously closed at $2.42.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on SANA shares. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Sana Biotechnology in a research note on Monday, November 11th. JMP Securities cut Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. Finally, Citigroup raised their target price on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, August 9th.

Sana Biotechnology Stock Performance

The stock has a market cap of $549.24 million, a P/E ratio of -1.73 and a beta of 1.44. The business’s 50-day moving average price is $3.92 and its 200-day moving average price is $5.54.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. As a group, equities research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total value of $612,000.00. Following the transaction, the director now directly owns 2,848,121 shares in the company, valued at $11,620,333.68. The trade was a 5.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 31.10% of the company’s stock.

Institutional Trading of Sana Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in SANA. Vanguard Group Inc. boosted its stake in Sana Biotechnology by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock worth $121,552,000 after purchasing an additional 2,358,089 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Sana Biotechnology by 2.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,695,459 shares of the company’s stock worth $36,956,000 after buying an additional 101,434 shares in the last quarter. Capital World Investors boosted its position in shares of Sana Biotechnology by 255.8% during the first quarter. Capital World Investors now owns 5,449,035 shares of the company’s stock worth $54,490,000 after acquiring an additional 3,917,728 shares during the last quarter. Integral Health Asset Management LLC boosted its position in shares of Sana Biotechnology by 22.4% during the second quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $6,552,000 after acquiring an additional 220,000 shares during the last quarter. Finally, Zimmer Partners LP bought a new stake in Sana Biotechnology in the 1st quarter valued at $2,025,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.